Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2023-06-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
第五届董事会第十七次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details decisions such as the cancellation of a subsidiary, approval of stock incentive plan conditions, and approval of loan applications and guarantees. The document includes voting results and references to related announcements but does not contain financial statements or detailed financial analysis. It is a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1521 characters), and it is not a report or financial statement itself but an announcement of board decisions.
2023-06-20 Chinese
关于为控股子公司向银行申请授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing a guarantee for a loan application by its controlling subsidiary. It details the guarantee amount, the subsidiary's financial data, board approval, and risk assessment. There are no financial statements or comprehensive financial performance data presented. The document is a disclosure of a financing-related guarantee arrangement, not a full financial report or earnings release. It fits best under Capital/Financing Update (CAP) as it updates on financing activities and guarantees provided by the company.
2023-06-20 Chinese
第五届监事会第十三次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the approval of the lifting of restrictions on a stock incentive plan. It includes details about the meeting, voting results, and references another announcement for more details. The document is short (936 characters) and primarily serves as an official announcement of a board decision rather than a full report or detailed financial disclosure. It does not contain financial statements, earnings data, or detailed management discussion. It is not a report publication announcement since it contains substantive content about the meeting resolution itself. The content fits best under Board/Management Information (MANG) as it relates to decisions made by the supervisory board regarding management incentive plans and internal governance matters.
2023-06-20 Chinese
监事会关于2020年限制性股票激励计划首次授予的第三个解除限售期解除限售激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the verification of the list of incentive recipients for the third release period of the 2020 restricted stock incentive plan. It references compliance with company law, securities law, and stock incentive management regulations. The content focuses on the legality and conditions of stock incentive release, not on financial results, management changes, or shareholder votes. It is a regulatory compliance and internal verification document related to stock incentives, not a financial report or announcement of voting results. It does not fit categories like Annual Report, Earnings Release, or Voting Results. It is best classified as a Regulatory Filing (RNS) because it is a compliance-related supervisory board statement without financial data or report publication.
2023-06-20 Chinese
独立董事关于关于2020年限制性股票激励计划首次授予的第三个解除限售期解除限售条件成就事项的独立意见
Governance Information Classification · 90% confidence The document is an independent opinion from independent directors regarding the achievement of conditions for lifting restrictions on a 2020 restricted stock incentive plan. It references legal and regulatory frameworks and confirms compliance with the plan and company rules. The content focuses on governance and compliance related to stock incentive plans rather than financial results, audit, or management reports. It is not a full report but an official opinion related to governance and stock incentive conditions. This fits best under Governance Information (CGR) as it details governance-related approval and compliance matters.
2023-06-20 Chinese
关于2020年限制性股票激励计划首次授予的第三个解除限售期解除限售条件成就的公告
Director's Dealing Classification · 95% confidence The document is an official announcement from a company regarding the achievement of conditions for the third unlocking period of a 2020 restricted stock incentive plan. It details the number of shares unlocked, the relevant board and supervisory meetings, performance conditions met, and legal opinions. The content focuses on stock incentive plan details, unlocking of restricted shares, and compliance with regulatory requirements. It is not a full financial report, earnings release, or management discussion. It is a formal announcement about the unlocking of restricted shares under a stock incentive plan, which relates to share transactions by insiders or executives. Therefore, the document fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives, including stock incentive plan unlockings and related share dealings.
2023-06-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.